Solomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., … McMurray, J. J. V. (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet, 380(9851), 1387–1395. https://doi.org/10.1016/s0140-6736(12)61227-6

Solomon, Scott D., Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, et al. “The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.” The Lancet 380, no. 9851 (October 2012): 1387–95. https://doi.org/10.1016/s0140-6736(12)61227-6.

Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012 Oct;380(9851):1387–95.

Solomon, Scott D., et al. “The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.” The Lancet, vol. 380, no. 9851, Elsevier BV, Oct. 2012, pp. 1387–95. Crossref, doi:10.1016/s0140-6736(12)61227-6.

Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. Elsevier BV; 2012 Oct;380(9851):1387–1395.